SecurityASX:WBC / WESTPAC BANKING CORPORATION
Institutional Owners0

Institutional Stock Ownership and Shareholders

WESTPAC BANKING CORPORATION (ASX:WBC) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include .
WESTPAC BANKING CORPORATION (ASX:WBC) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Important Note!
Note: We do not currently have a CUSIP on file for this security. That means we are unable to search institutional fund filings (13F's) for this company, which means there may be institutional holders that we are unaware of. If you know the CUSIP or would like us to research and update this security, please let us know by leaving a message in the Welcome Group.
File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

NZ shares shrug off Synlait slump, join global rally

2018-09-19 nzherald.co.nz
New Zealand shares rose as investors shrugged off a slightly gloomier outlook for Synlait Milk and joined a global rally as the latest bout in the US-China trade war wasn't as harsh as feared.

33 'Safer' Dividend Financial WallStars Fetch 3.6-12.6% Yields For September

2018-09-12 seekingalpha
WallStars are distinguished by positive broker target-price upsides. Top 10 Financial Services 'safer' dividend WallStars, MET, TCRD, PFG, PRU, APO, WBK, DGICA, LAZ, IVZ, & BGCP averaged 25.23% 9/7/18. (9-0)

Yes Bank raises $400 million through syndicated loan facility

2018-09-11 moneycontrol
Private sector lender Yes Bank Tuesday said it has raised $400 million (approx Rs 2,894 crore) through syndicated loan facility, borrowed out of its IFSC Banking Unit (IBU) in Gujarat International Finance Tec City (GIFT). The bank said this amount will be utilised to support the IBU's growing business.

NZ dollar holds near two-year low against pound

2018-09-11 nzherald.co.nz
The New Zealand dollar held near a two-and-a-half-year low on optimism the UK and European Union will reach an amicable split as early as November.

Australia's ANZ raising home loan rates due to higher funding costs

2018-09-06 theedgemarkets
(Sept 6): Australia and New Zealand Banking Group said on Thursday it is raising its home loan interest rates in Australia, after taking note of higher funding costs, its business performance and prevailing market conditions.

NZ dollar holds gains as efforts to soothe Brexit pains calm investors

2018-09-06 nzherald.co.nz
The New Zealand dollar held overnight gains as positive headlines overnight about Brexit negotiations boosted global risk appetite.

Exclusive: Big Australian fund manager divests Commonwealth Bank over misconduct

2018-09-05 reuters
SYDNEY (Reuters) - Wealth manager Perpetual Ltd (PPT.AX) said it has divested Commonwealth Bank of Australia (CBA.AX) from its A$1.3 billion ($933.6 million) ethical fund due to revelations of corporate misconduct, the first big institutional investor to do so.

UPDATE 2-Australia's Westpac fined for bad mortgage system amid bank inquiry

2018-09-04 reuters
* Analysts say financial impact from ASIC fine “immaterial” (Recasts on regulator crackdown, adds shares, analysts)

Australia holds key rate as sliding currency stimulates growth

2018-09-04 theedgemarkets
(Sept 4): Australia kept interest rates at a record low Tuesday, as it has for the past two years, while a currency sliding toward 70 U.S. cents offers the prospect of additional stimulus for the economy.

NZ dollar falls v Aussie after RBA maintains neutral tone

2018-09-04 nzherald.co.nz
The New Zealand dollar fell against the Aussie after the Reserve Bank of Australia kept the benchmark rate on hold and didn't opt for a more dovish tone, despite Westpac Banking Corp's out-of-cycle rate hike.